Zugriffe | |
---|---|
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program | 152 |
März 2024 | April 2024 | Mai 2024 | Juni 2024 | Juli 2024 | August 2024 | September 2024 | |
---|---|---|---|---|---|---|---|
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program | 3 | 0 | 4 | 1 | 13 | 9 | 3 |
Zugriffe | |
---|---|
2021_Frost_etal.pdf | 200 |